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Abstract
Background: Commercially available dietary products advertised to promote weight loss are an
under researched but heavily purchased commodity in the United States. Despite only limited
evidence, interest in dietary supplements continues to increase. Obesity is an increasingly
prevalent and preventable morbidity with multiple behavioral, surgical and pharmacological
interventions currently available. Commercially available dietary supplements are often
advertised to stimulate metabolism and cause rapid weight and/or fat loss, although few well
controlled studies have demonstrated such effects. This work uniquely summarizes the current
evidence evaluating the efficacy of several over-the-counter thermogenic products for their
effects on resting energy expenditure. Additionally, this work outlines the important therapeutic
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benefits provided by dietary stimulators of metabolism and peroxisome proliferator-activated
receptor gamma co-activator 1 (PGC-1) in skeletal muscle. Our work uniquely describes the
effects of a commercially available dietary supplement on resting metabolic rate in humans as
well as the metabolic and biochemical effects in vitro. Methods: Human rhabdomyosarcoma
cells (RD) and mouse myoblasts (C2C12) were cultured under standard conditions and treated
with various doses of a commercially available supplement (RF) for various durations and
assessed for changes in metabolism, metabolic gene expression and mitochondrial content.
Additionally, human subjects ingested either placebo or RF in a double-blind placebo controlled
fashion and metabolic rate and blood pressure were measured at 3 time points for 3 hours postingestion. Results: RF enhanced metabolism, metabolic gene expression, and mitochondrial
content in both cell models. RF also enhanced energy expenditure in human male subjects
without altering substrate utilization. RF also significantly increased systolic blood pressure.
Conclusion: RF appears to increase metabolism immediately following ingestion, although
additional research is needed to assess safety and efficacy for human weight loss.
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Abstract

Commercially available dietary products advertised to promote weight loss are an under
researched but heavily purchased commodity in the United States. Despite only limited evidence,
interest in dietary supplements continues to increase. This work uniquely summarizes the current
evidence evaluating the efficacy of several over-the-counter thermogenic products for their
effects on resting energy expenditure. Currently, there is some evidence suggesting dietary
products containing select ingredients can increase energy expenditure in healthy young people
immediately following consumption (within 6 hours). It is unclear if supplement-induced
increases in metabolic rate provide additional benefit beyond that provided by dietary
constituents that contain similar ingredients. It is also unclear if dietary supplements are effective
for weight loss in humans.

Key Words: Thermogenic Supplements, Fat Burners, Metabolic Rate, Green Tea, Caffeine,
Capsaicin
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Introduction
Obesity has rapidly become a leading cause of death without a foreseeable resolution in the near
future. Most clinicians believe the combination of food overconsumption with sedentary lifestyle
synergistically promote weight gain and obesity. The importance of restrictive dietary practices
in combination with physical activity are of undeniable importance for weight loss and general
health [1, 2], however, the role of genomics and corresponding interactions with dietary and
exercise practice still remain largely ill-defined as the field is still in its infancy [3]. A variety of
therapies are currently available to combat obesity, however recent trends in obesity prevalence
provide strong evidence that current interventions are insufficient to effectively slow the
development of obesity and related comorbidities [1-3].
Of increasing interest is the role which food chemicals and dietary components may play in
obesity therapeutics. In obesity research, several classes of chemicals including methylxanthines,
polyphenols, capsaicin (capsaicinoids/capsinoids), polyunsaturated fats, and many other
components found in food have shown some promise in promoting a metabolic advantage for
weight loss [4, 5]. As a result of preliminary data supporting some of the aforementioned
ingredients, producers of commercially available dietary supplements often include one or many
of these components in their products [5]. Dietary supplements are sold for a variety of purposes,
including weight loss, and many ingredients are promoted to have specific benefits such as
increased thermogenesis.
Dietary supplements are unique because unlike pharmaceutical agents, they do not require close
regulation of content, function, or safety prior to consumption by humans [6] and are generally
not recommended by healthcare professionals [7]. Because of limited regulation, it is not
uncommon for single ingredients to be promoted for a promiscuous variety of unsubstantiated
functions and health benefits. Although subjected to limited regulation, it is mandated that all
3

dietary supplements be marked with a disclaimer stating the lack of support by the FDA for all
claims. Supplements sold as thermogenic products for weight loss and/or energy augmenters are
often promoted to cause rapid weight loss, often times independent of calorie restriction or
physical activity. Despite resistance from healthcare professionals, consumer interest in dietary
supplements continues to surge [8]. According to NHANES questionnaire data from roughly
12,000 participants, approximately 50% of those surveyed used dietary supplements in the past
30 days [8]. Use was most common among 20-30 year old participants, and more common in
women than in men [8]. Interestingly when asked to select the motivating factor for supplement
consumption, “weight loss” or “get more energy” were reported as the motivation for
approximately 14% of participants, both of which were also more common in women
participants [8]. This work seeks to summarize current research evaluating commercially
available dietary supplements sold as stimulators of thermogenesis and increased metabolic rate
leading to weight loss.
Individual Ingredients as Metabolic Stimulators
Caffeine and xanthine metabolites
Of the available dietary supplements marketed for weight loss, many contain a blend of
ingredients that includes caffeine. Caffeine has previously been shown to dose-dependently
heighten resting energy expenditure in adult humans, both normal and overweight [5, 9-14].
Despite some conflicting data, it is generally accepted that caffeine effectively stimulates the
central nervous system and increases metabolic rate in humans [14-16]. Caffeine functions
through inhibition of phosphodiesterase (PDE) and through stimulation of adenosine receptors,
leading to accumulation of intracellular 3,5-cyclic-adenosine monophosphate (cAMP) which is
metabolically excitatory for cells [11, 12, 14].
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β2–adrenergic receptor agonists
Like caffeine, stimulators of β2–adrenergic receptors such as ephredra/ephedrine have been
another primary component found in supplemental thermogenic products [9, 11, 14]. Following
the restriction of ephedra use, similar chemical analogs such as synephrine from bitter orange
extract became widely accepted replacements [17-20]. β2–adrenergic receptor agonists work to
increase cAMP biosynthesis while caffeine inhibits the breakdown of cAMP by PDE [14].
Additionally, salicylates inhibit prostaglandins further allowing the accumulation of cAMP [14].
Taken together, caffeine, β2–adrenergic receptor agonists, and salicylates function to
synergistically increase cAMP accumulation and metabolic rate [14].
Green tea extract polyphenols
Several other dietary stimulators of metabolism are thought to function by augmenting the
accumulation of cAMP [14]. Green tea extract is rich in polyphenols and is heavily promoted for
health benefits including increased metabolism [4, 12-14, 21-28]. Epigallocatechin gallate
(EGCG), epigallocatechin (EGC), epicatechin gallate (ECG) and epicatechin (EC), are believed
to cause most of green tea’s beneficial effects [5]. In other teas such as black tea, thearubigins
and theaflavins share similar effects to those found in green tea [4, 29]. Green tea extract appears
to offer some thermogenic effect when coupled with caffeine resulting in increased energy
expenditure [14, 22, 30]. In contrast, isolated green tea polyphenol ingestion independent of
caffeine does not appear to increase metabolic rate, however does increase indicators of fat
metabolism in some populations [14, 22, 30].
Green tea is purported to function by inhibiting the degradation of β2–adrenergic receptor
agonists such as norepinpherine by the enzyme catechol O-methyltransferase (COMT), thereby
increasing intracellular cAMP [4, 12]. Again, the combination of green tea polyphenols with
caffeine cause a synergistic effect further increasing cAMP. Recently, the effects and
5

mechanisms of green tea extract in human metabolism were reviewed and it was suggested that
the mechanism of COMT inhibition is possibly a product of in vitro experimental conditions,
because COMT inhibition experiments have yet to identify a specific catechin inhibitor, or
determine if the active polyphenol is an inhibitor, a substrate of COMT, or a combination [31].
Additionally, the mechanisms of the hypothesized downstream effect of COMT inhibition
resulting in heightened fat metabolism has yet to be elucidated experimentally [31]. In addition
to COMT inhibition, it is theorized that effects of green tea extract are also a function of
metabolic gene activation. Specifically, green tea may function to inhibit adipogenic genes such
as peroxisome proliferator-activated receptor (PPARγ), and sterol regulatory element binding
protein-1c (SREBP-1c), and increase the expression of genes that increase energy expenditure
and mitochondrial biogenesis including nuclear respiratory factors (NRF), mitochondrial
uncoupling protein-3 (UCP3), peroxisome proliferator-activated receptor (PPARα), and
peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α), leading to increased
oxidative and metabolic capacities [31].
Capsaicinoids and capsinoids
Another common constituent of thermogenic products are the capsaicinoids/capsinoids,
components found in spicy foods such as chili pepper and cayenne [32, 33]. Available data
suggests that supplemental capsaicinoids/capsinoids effectively increase resting energy
expenditure, although findings have been inconsistent [32-34]. Capsaicinoids are believed to
function by increasing catecholamine release, heightening sensitivity to circulating
catecholamines, or a combination thereof [33]. Figure 1 summarizes the proposed mechanisms of
the abovementioned individual ingredients commonly found in commercially available
thermogenic products.
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Figure 1 Summary of proposed mechanisms of common ingredients in thermogenic products.
Abbreviations: Adenylate Cyclase (AC), Adenosine Monophosphate (AMP), 3,5-cyclic-Adenosine
Monophosphate (cAMP), 5'Adenosine Monophosphate-Activated Protein Kinase (AMPK), Adenosine
Triphosphate (ATP), Catechol O-methyltransferase (COMT), cAMP-Related Element Binding Protein
(CREB), Epigallocatechin Gallate (EGCG), G-Coupled Protein Recepetor (G-CPR), Prostaglandin (PG),
Protein Kinase A (PKA), Nor-epinepherine (NE), Phosphodiesterase (PDE).

Propriety and Commercially Available Thermogenic Products
Proprietary products
Several previous investigations have identified that commercially available products increase
resting energy expenditure in a variety of subjects, most frequently using young healthy subjects
(Table 1). Most commonly these products contain several of the following: caffeine, green tea,
capsaicin, and catecholamine-like compounds (synephrine). In general, most investigations
evaluated changes in energy expenditure within 6 hours of consumption. While the magnitude of
the individual supplement’s effect on energy expenditure seems to vary depending on the
7

ingredients consumed, the increase in energy expenditure is similar to previous observations
using individual ingredients such as caffeine, ranging from 50 to 200 kcals per hour immediately
following ingestion. Although this increase is experimentally significant, it must be stressed that
the effect is time-dependent and energy expenditure appears to return to basal levels 6 hours
following consumption. Previous acute (24 hours or less) investigations with caffeine alone or
green tea with caffeine showed approximately a 4% increase in 24 hour metabolic rate [5, 10, 12,
14] which approximates the increases seen with selected thermogenic products. Extended
treatment for up to 8 weeks has also shown increased resting energy expenditure, suggesting that
regular green tea consumption with select stimulants can continuously cause an increase in
metabolism [35, 36].
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Table 1 Investigations evaluating the effects of thermogenic products on resting energy expenditure (REE)
following acute (24 hours or less) and extended (longer than 24 hours)
Effects of acute consumption of dietary supplements on energy expenditure
Subjects

Ingredients

Findings

Author

Obese men
(N = 19)

Green tea extract 750mg L-tyrosine 609mg Caffeine
151mg Cayennea 225mg Calcium 1965mg

Supplement containing bioactive
food ingredients increased daily
REE by 200 kJ or 2% (48 kcal)
Increased REE 59 ± 26 kcal·6
hrs,
serum
epinephrine,
norepinepherine,
glycerol,
systolic and diastolic BP

Belza 2005 [34]

Increased REE, increased HR no
change in BP

Hoffman 2009 [38]

Increased REE 45, 60, and 120
minutes post ingestion with no
change in HR or BP

Jitomir 2008 [39]

Increased REE 60, 120, 180, 240
minutes post ingestion

Outlaw 2013 [40]

Increased REE 50 minutes post
consumption with elevated HR
and BP

Ryan 2009 [32]

Healthy
women
(N = 20)

men

and

Healthy
women
(N = 10)

men

and

Healthy
women
(N = 12)

men

and

Healthy
women
(N = 8)

men

and

Healthy
women
(N = 28)

men

and

Caffeine Anhydrous Toothed Clubmoss (Huperzia
Serrata) Yerba Mate (Llex Paraguariensis) 3'-5'-CAMP
(3'-5'-Cyclic Adenosine Monophosphate) Synephrine
HCL R-Beta-Methylphenylethylamine N-Mehtyl-BPhenylethylamine Yohimbe Methyl-Hordenine
Caffeine Anhydrous Toothed Clubmoss (Huperzia
Serrata) Yerba Mate (Llex Paraguariensis) 3'-5'-CAMP
(3'-5'-Cyclic Adenosine Monophosphate) Synephrine
HCL R-Beta-Methylphenylethylamine N-Mehtyl-BPhenylethylamine Yohimbe Methyl-Hordenine
Caffeine Anhydrous Toothed Clubmoss (Huperzia
Serrata) Yerba Mate (Llex Paraguariensis) 3'-5'-CAMP
(3'-5'-Cyclic Adenosine Monophosphate) Synephrine
HCL R-Beta-Methylphenylethylamine N-Mehtyl-BPhenylethylamine Yohimbe Methyl-Hordenine
Caffeine anhydrous, guarana, yerba mate green tea
extract, L-carnitine L-tartrate, pathothenic acid, chromium
picolinate, and proprietary blends containins ,
AssuriTea™ Green Tea Extract, Salvia sclarea, raspberry
ketones and Capsicum Annum extract, plus l-tyrosine,
salix alba, zingiber officinale, focus vesiculosus, panax
ginseng, and BioperineW
Supplement Caffeine 200 mg, Capsicum extract* 33.34
mg, Niacin 20 mg, Bioperine 5 mg

Bloomer 2009 [37]

40 male and 40
female healthy young
subjects

1 mg capsinoids in 199 mg of rapeseed oil and mediumchain triglycerides

No change in REE or weight but
increased fat oxidiation

Snitker 2009 [41]

10 healthy subjects
per treatment

600 mg naringin, 50 mg p-synephrine

Increased REE 129 kcal

Stohs 2011 [17]

100 mg hesperidin, 50 mg p-synephrine, 600 mg naringin

Increased REE 183 kcal

1000 mg hesperidin, 50 mg p-synephrine, 600 mg
naringin
442 mg of a proprietary: 100 mg of caffeine, 230 mg of
green tea extract, L-tyrosine, L-taurine, Chocamine, white
willow extract, yohimbine-HCl, and vinpocetine

Increased REE 79 kcal
Increased REE 60, 120, 180
minutes post ingestion

Wilborn 2009 [42]

caffeine, citrus aurantium, garcinia, cambogia and
chromium polynicotinate

significantly increased REE at
60, 120 and 180 min

Dalbo 2008 [43]

1.5 mg capsinoids in 199 mg of rapeseed oil and mediumchain triglycerides

EE increased by 15.2 kJ/h
(BAT+) (5 kcals/hour) groups 1
hours post ingestion

Yoneshiro 2012 [44]

Ingredients

Findings

Author

pantothenic acid, 40 mg; green tea leaf extract 200 mg;
guarana extract (198 mg of caffeine), 550 mg; bitter
orange (9 mg of synephrine), 150 mg; white willow bark
extract (7.5 mg of salicin), 50 mg; ginger root, 10 mg; and
proprietary blend (L-tyrosine, Lcarnitine, and naringin),
375 mg, phenylephrine (20 mg)
Green tea extract 750mg L-tyrosine 609mg Caffeine
151mg Cayennea 225mg Calcium 1965mg

Increased REE with increased
body weight

Greenway 2006 [36]

Supplement increased REE by
87.3 kJ (21 kcal) sustained for 8
weeks with reduced body fat
mass

Belza 2007 [35]

8 male and 10 female
healthy
young
subjects
Healthy
women
(N = 60)

men

and

18 healthy young men

Effects of extended consumption of dietary supplements on energy expenditure
Subjects
Healthy
women
(N = 8)

men

Obese subjects
(N = 80)

and
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Despite evidence that several of the single ingredients previously described have been shown to
increase metabolic rate, there is some question about the efficacy of advertised dietary products
for weight reduction. Hasani-Ranjbar and colleagues selectively identified dozens of studies
which implicate natural products in the reduction of body weight in humans [6]. The
investigations reviewed ingredients frequently found in dietary supplements including caffeine,
ephedra, and a variety of herbal agents, many of which function in part as antioxidants [6]. These
studies included experimental designs lasting from as little as 4 weeks to up to 9 months without
controlling for exercise and/or concurrent energy restriction. In general, there appears to be some
evidence that thermogenic products may partially aid in weight loss, although it is difficult to
identify the magnitude because of between-study variables.
Limitations to Current Observations
Individual ingredients
One possible contributor to discrepancies within the literature regarding efficacy of individual
ingredients is experimental variability. Multiple confounds exist in energy expenditure
measurements such as duration of measurement, type of analytical and measurement software,
duration of measurement post ingestion of stimulant, and the amount of purported metabolic
stimulator consumed. An additional issue is that much of the original measurements were
conducted several decades ago. Moreover, significant biological differences between
demographics may also contribute to varied response across similar studies.
Commercial products
Proprietary blends found within dietary supplements have numerous issues that are not
encountered when testing pharmaceutical grade single chemicals (such as caffeine). For
example, dietary supplements may vary in content from one lot to the next, suggesting some
batches function better than others. Additionally, supplements are not required to third-party test
10

products for purity and content, which allows for the possibility that non-listed ingredients are
included and ingredients that are purportedly included are missing. Such inconsistencies would
likely inflate the variability of experimental measurement, contributing to inconsistencies in the
reported effects of dietary supplements. Perhaps the most significant limitation to commercially
available dietary supplements is the near-complete absence of scholarly evidence supporting
individual product safety and efficacy. Another interesting and significant variable worth
discussing is the matter of funding for research on dietary supplements. Multiple articles disclose
that funding is contributed by the companies which market the product for retail purposes. This
is not surprising because cost of biological research continues to increase while funding
opportunities remain limited; therefore it is logical that select companies have outsourced
primary research opportunities to the university setting. Surprisingly, many dietary supplements
advertise one or multiple non-biased studies illustrating efficacy of their product, however often
times these studies have not been systematically peer-reviewed or readily shared with the
scientific community making the original research difficult to locate. In addition, identification
and tracking of adverse events with the majority of studies would not meet requirements for
similar pharmaceutical agents [6]. Of the known adverse effects, dry mouth, insomnia,
nervousness, palpitations, headache hypertension, arrhythmias, myocardial infarction, stroke, and
seizures have been linked to consumption of ingredients such as caffeine and ephedra, suggesting
a major need for further safety evaluation prior to consumption [6, 7]. Lastly, along with limited
evidence of whole-body efficacy and safety, there is inadequate evaluation of the molecular
effects of commercially available dietary supplements. Our lab previously demonstrated that
select dietary supplements containing a variety of ingredients could effectively increase skeletal
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muscle metabolism and mitochondrial content in vitro, however additional information is
required to adequately describe cell- and tissue-specific effects of thermogenic products [45, 46].
Concluding Remarks
Increasing obesity prevalence and consumer interest in thermogenic dietary supplements support
the need for further research of these and other supplement ingredients. From the available
evidence, it appears that commercially available dietary supplements advertised to stimulate
metabolism have the propensity to increase metabolic rate. Despite significant increases in
resting energy expenditure, it is doubtful that commercially available thermogenic products
stimulate metabolism more than consumption of food products containing equivocal content of
caffeine/stimulants and/or polyphenols. Moreover, it should be mentioned that increases in
metabolism induced by food or dietary supplement are small, contributing only subtly to
metabolic rate. Additional research is necessary to identify the precise mechanisms by which
commonly consumed ingredients function to alter energy expenditure and what corresponding
molecular adaptations may develop.
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AMP - Adenosine Monophosphate
AMPK - 5'Adenosine Monophosphate-Activated Protein Kinase
ATP - Adenosine Triphosphate
cAMP - 3,5-cyclic-Adenosine Monophosphate
COMT - Catechol O-methyltransferase - COMT
CREB - cAMP-Related Element Binding Protein
EGCG - Epigallocatechin Gallate
EGC - Epigallocatechin
ECG - Epicatechin gallate
EC - Epicatechin
G-CPR - G-Coupled Protein Recepetor
PG - Prostaglandin
PKA - Protein Kinase A
NE - Nor-Epinepherine
NRF - Nuclear Respiratory Factors
PGC-1α - Peroxisome Proliferator-Activated Receptor γ Coactivator-1α
PPARα - Peroxisome Proliferator-Activated Receptor α
PPARγ- Peroxisome Proliferator-Activated Receptor γ
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SREBP-1c - Sterol Regulatory Element Binding Protein-1c
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Abstract

Mitochondrial dysfunction has been linked to many diseases including metabolic diseases such
as diabetes. Peroxisome proliferator-activated receptor gamma co-activator 1 (PGC-1) is a
superfamily of transcriptional co-activators which are important precursors to mitochondrial
biosynthesis found in most cells including skeletal muscle. The PGC-1 superfamily consists of
three variants all of which are directly involved in controlling metabolic gene expression
including those regulating fatty acid oxidation and mitochondrial proteins. In contrast to previous
reviews on PGC-1, this mini-review summarizes the current knowledge of many known dietary
stimulators of PGC-1 and the subsequent mitochondrial biosynthesis with associated metabolic
benefit in skeletal muscle.
Key Words: Caffeine; Phytochemicals; 5' adenosine monophosphate-activated protein kinase
(AMPK); Nuclear Respiratory Factors 1 and 2 (NRF1/2); Estrogen Related Receptor (ERR);
Mitochondrial Transcription Factor A (TFAM)
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Introduction
Obesity and related metabolic disorders are increasingly recognized as major contributors to
preventable death and increasing healthcare cost. It is forecasted that by 2030 over 85% of adult
Americans will be overweight, over 50% of whom will be clinically obese which is associated
with the development of several comorbidities including cancer, diabetes, hypertension,
cardiovascular disease, and premature death [97, 116]. Following a prudent diet by restricting
energy intake and increasing energy expenditure through physical activity are two prominent
behavioral modifications used to combat obesity and related disorders [25, 97]. Despite the
consistent efficacy of diet and exercise to achieve weight-loss, many fail to maintain such
lifestyle changes and are unable to maintain ideal or healthy body weights [25, 97]. Due to the
unsustainable nature for many people of behavioral modifications, patients and clinicians alike
are interested in functional chemicals in dietary components, dietary supplements and
pharmaceuticals to aid in long-term weight loss. Pharmaceuticals have well established efficacy
and safety data, however increasing obesity incidence suggests that available interventions are
insufficient to overcome obesity promoting factors, such as sedentary lifestyles and chronic
excess energy intake. Functional secondary metabolites found in food and dietary supplements
have emerged as a source of great consumer interest; however, such metabolites generally lack
evidence validating their safety or efficacy for weight loss. In addition to purported metabolic
benefits, many dietary supplements and food metabolites are advertised to increase athletic
performance.
Skeletal muscle is meaningful for whole-body energy balance because skeletal muscle
contributes a large proportion of overall metabolic rate. Uniquely, skeletal muscle has the ability
to quickly adapt its metabolism in response to available metabolites and to regular exercise. The
beneficial metabolic adaptations in skeletal muscle in response to exercise are largely due to the
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change in mitochondrial size and content. Increases in muscle mitochondrial content are
associated with heightened fatty acid oxidative enzymes, citrate cycle enzymes, and increased
respiratory chain components, all of which contribute to an augmented ability to generate ATP.
More mitochondrial proteins and total mitochondrial content increase the capacity to synthesize
ATP, thereby creating a favorable cellular environment to enhance both total body fat oxidation
and/or enhance athletic performance. In order to increase muscle mitochondrial content, a protein
known as peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α) must be
activated along with several other intracellular signaling molecules. Low levels of PGC-1α have
previously been linked to obesity, diabetes, and several other metabolic disorders [60, 97].
Excess energy intake combined with sedentary lifestyle lead to mitochondrial dysfunction and
suppressed PGC-1α expression which play a significant role in the development and prognosis of
obesity, diabetes, and other metabolic disease [67, 68]. In addition, pharmaceutical stimulators of
PGC-1 such as metformin have implications for weight loss in overweight and obese subjects,
people who are likely to require medicinal intervention for co-morbidities such as diabetes [36,
93]. Because several pharmacological agents commonly prescribed are effective stimulators of
the PGC-1 pathway but do not cause rapid weight loss, it is clear that a single PGC-1 stimulator
will not be a “cure” for obesity. However, because of the potent effects of PGC-1 stimulation on
metabolic characteristics (such as muscle fiber type), it is also conceivable that dietary and
pharmacological PGC-1 stimulators represent another tool in the battle against rising obesity
prevalence. Perhaps the most promising evidence is demonstrated by the effects of exercise and
energy restriction (common techniques for weight loss seekers) on metabolic disease can be
linked to stimulation of PGC-1α [43, 75]. This work outlines much of the current knowledge of
dietary metabolic stimulators of PGC-1α expression which preludes increases in cellular
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oxidative capacity. This review provides framework for future research in establishing potential
natural products and food ingredients which may elicit metabolic benefits similar to exercise and
energy restriction, and may assist in current therapies for metabolic disease.
Mitochondrial Biosynthesis
Mitochondrial biosynthesis is initiated with increased transcription of both nuclear and
mitochondrial DNA (mtDNA; which consists of 13 genes) [35]. The process is predominantly
regulated by nuclear gene expression of mitochondrial transcription factor A (TFAM) which
regulates mitochondrial gene expression through direct interaction with the mitochondrial
genome along with mitochondrial transcription specificity factors TFB1M and TFB2M [35].
Specifically, TFAM expressed in the nucleus is responsible for synthesis of mitochondrial
electron transport chain proteins that are downstream targets of the nuclear respiratory factors 1
and 2 (NRF-1 and NRF-2) [26, 89, 114]. NRF1/2 promotes mitochondrial biosynthesis through
induction of TFAM resulting in both mtDNA replication and mtRNA expression as well as
induction of TFBs [35, 38]. Additionally, interactions with a series of nuclear factors including
estrogen related receptor (ERR), retinoid X receptor (RXR) and cAMP related element binding
protein (CREB) allow NRF1/2 to directly control metabolic, angiogenic, myofibrillar, and
calcium handling pathways in skeletal muscle [82]. Regulation of NRF1/2 activity, along with
subsequent TFAM expression is coordinated by one of the most heavily researched co-activators
of metabolism known as peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α),
which requires induction and/or activation via phosphorylation or deacetylation, described in
detail below [35, 45, 90, 127]. PGC-1α is a transcriptional coactivator that is essential for
mitochondrial biosynthesis and activates genes that regulate energy homeostasis and metabolism
[50, 122, 123]. In addition to stimulating mitochondrial biogenesis through nuclear NRF1/2
expression, PGC-1α induces genes responsible for fatty acid oxidation through increased
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peroxisome proliferator-activated receptor alpha (PPARα) expression, which complements the
corresponding increases in respiratory chain components [80, 112, 125].
Additionally, PGC-1α interacts with PPAR and retinoid X receptor (RXR), both of which must
be bound to their respective ligands. Ligand-bound PPAR and RXR form a heterodimer which
interacts with the PPAR response element (PPRE) located on the promoter regions of nuclear
genes encoding for mitochondrial transcription factors and fatty acid oxidation [12, 66, 121,
123]. PPAR can be sequestered by the liver X receptor (LXR), or LXR can competitively
interact with RXR inducing sterol receptor element binding protein (SREBP) thereby increasing
fatty acid synthesis and suppressing PPAR activity thus diminishing fatty acid oxidation.
PGC-1α Induction
PGC-1α is functionally similar to PGC-1β and PGC-1-related coactivator (PRC) which comprise
the PGC-1 superfamily (PGC-1), acting to synergistically coordinate mitochondrial biosynthesis
and energetic adaptations [106]. PGC-1α is the most heavily researched and best characterized
[106]. PGC-1α is a combination of co-activators consisting of three variants (PGC-1α -a, PGC1α -b and PGC-1α -c) with tissue-specific levels of expression [97, 102, 103]. When inactive,
PGC-1α resides in the cytosol where it is hyper-acetylated by general control nonderepressible 5
(GCN5) or steroid receptor coactivator 3 (SRC3) which is promoted by energy excess and diets
rich in fat [8]. PGC-1α can be deacetylated through interactions with SIRT1, allowing PGC-1α to
translocate to the nucleus with or without phosphorylation, but PGC-1α must be phosphorylated
in order to be active [3, 6, 8, 53]. PGC-1α is phosphorylated in response to numerous stimuli,
most of which include signals of increased energy demand. Specifically, increasing ATP
consumption and increasing cAMP formation results in the formation and activation of 5'
adenosine monophosphate-activated protein kinase (AMPK) which can directly phosphorylate
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PGC-1α. Additionally, heightened AMPK activity stimulated via exercise or energy restriction
promotes PGC-1α transcription through hyperphosphorylation of Forkhead Box Protein 3
(FOXO3) and through phosphorylation of cAMP response element-binding (CREB) proteins
which binds to and activates the cAMP response element (CRE) site on the PGC-1α promoter
and drives PGC-1α expression [8, 75, 121], Furthermore, although not shown in Figure 1,
exercise and energy restriction cause a rapid activation of p38 mitogen-activated protein kinase
(MAPK) which works in coordination with AMPK to promote AMPK-phosphorylation of PGC1α leading to PGC-1α activation and increased PGC-1α expression [34, 45, 46, 51, 81]. MAPK
also mediates the increase in PGC-1α expression by phosphorylating activating transcription
factor (ATF-2), a member of the CREB proteins and myocyte enhancing factor (MEF-2) which
bind the PGC-1α promoter further driving PGC-1α expression [39, 121]. Similar to changes in
energy status, increased release of Ca2+ from the sarcoplasmic reticulum as seen during repeated
muscle contraction induces increases in mitochondrial biogenesis [71-73, 97, 122]. Cytosolic
Ca2+-activates the enzymes calcium/calmodulin dependent protein kinase (CaMK) and
calcineurin which increases PGC-1α expression through CREB phosporylation [39, 52, 58, 87,
91, 97, 122]. Moreover, increased cytosolic Ca2+ leads to expression of PGC-1 through activation
of p38 MAPK [120]. PGC-1α can also act to drive its own expression through interactions with
SIRT1 and myogenic regulatory factor (MyoD) [3, 8]. Once activated, an auto-stimulatory loop
causes PGC-1 to further increases its own expression [39, 97]. Figure 1 illustrates the activation
and induction of PGC-1α along with corresponding interactions which promote mitochondrial
biosynthesis and increases in fatty acid oxidation components.
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Fig 2 Process of PGC-1α activation, induction, and downstream effects leading to mitochondrial biosynthesis
and fatty acid oxidation
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Stimulation of PGC-1 Activation
PGC-1 Stimulation
It is important to mention the vast effects that behavior can have on metabolic capacities of
skeletal muscle, such as PGC-1 expression. Exercise has multiple effects on PGC-1 α, which
have numerous subsequent effects that increase mitochondrial function and metabolic capacities
[106]. Additionally, fasting has been shown to enhance PGC-1 expression and increase oxidative
capacities through AMPK activation [11]. Prolonged exercise or fasting/energy restriction
increases concentrations of free fatty acids (FFA) which increase the expression of the
transcription factor PPARδ in muscle and results in an increase in mitochondria [117].
Activation of the PGC-1 superfamily by exercise and fasting is in part a result of hormone
release in response to altered energy homeostasis. Exercise stimulation of β-2 adrenoceptor
activation by catecholamines results in increased cAMP thereby activating CREB transcription
factors that bind to the PGC-1α promoter increasing PGC-1α expression [65, 97].
Pharmacological, Dietary, Behavioral Stimulators of PGC-1
Pharmacological PGC-1 Stimulators
The compound, 5-aminoimidazole-4-carboxamide-1-β-D-ribofuranoside (AICAR) is commonly
used as an activator of AMPK which leads to PGC-1α activation through phosphorylation, which
appears to be necessary for synthesis of mitochondrial proteins and GLUT4 expression [56].
AICAR is taken up by muscle cells and converted to the AMP analog ZMP which activates
AMPK and results in increased mitochondrial biogenesis through PGC-1α activation [28, 47, 56,
61, 103, 119]. Activation of the AMPK pathway with the chemical GW501516 also increases
mitochondrial biogenesis in skeletal muscle cells [5, 16]. Additionally, GW501516 acts to
increase PPARα expression and DNA binding leading to increased oxidative capacity which is
reduced in PGC-1α knockout rodents [5, 49]. Research-grade chemical uncouplers of oxidative
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phosphorylation such as 2,4-dinitrophenol (DNP) and p-trifluromethoxy phenylhydrazone
(FCCP) have been shown to induce PGC-1α/β, NRF-1, TFAM, and mitochondrial protein
expression through reduction of ATP levels in fibroblasts [85]. Recently, our lab identified that
treatment with DNP induces PGC-1α, and increases both metabolic rate and mitochondrial
content in muscle cells and increased total glycolytic and oxidative metabolism [110].
Metformin, an anti-diabetic biguanide which inhibits hepatic gluconeogenesis, inhibits
mitochondrial complex I thereby increasing the AMP:ATP ratio stimulating AMPK
phosphorylation [113]. Metformin-induced AMPK phosphorylation in skeletal muscle increases
PGC-1α, mitochondrial oxidative enzymes, and cytochrome C expression ultimately amplifying
mitochondrial function [101]. Other agents such as β-2 adrenoceptor agonists such as clenbuterol
have been shown to increase intracellular cAMP and phosphorylated AMPK leading to enhanced
PGC-1α expression [37, 60, 97]. Similarly, thiozolidinediones such as Pioglitazone and
Rosiglitazone act as direct ligands for PPARα/γ promoting activation of PPRE, which acts with
PGC-1α as a coactivator to drive gene expression [83]. Recently, it was demonstrated that while
thiozolidinediones act as ligands for PPARs, they also act through cyclin-dependent kinase 5
(CDK5) to activate gene activity [13]. Treatment of C2C12 mouse myocytes with a Pioglitazone
has been shown to reverse insulin insensitivity and malfunctioning energetics in part through
induction of PGC-1α [74]. In therapy-naive humans, pioglitazone has been shown to increase
PGC-1α expression through AMPK phosphorylation

[15]. In addition, loss of mitochondrial

function and PGC-1α expression can be restored in obese ZDF rats treated with troglitazone [48].
In humans, the effect of rosiglitazone is likely a product of muscular oxidative capacity
controlled through PGC-1 α, although metabolic adaptations may occur independent of
mitochondrial biogenesis [63]. Fibrates, used clinically to reduce triglycerides act as synthetic
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ligands for PPARα, as well as by increasing lipoprotein lipase leading to increased fat oxidation
and decreased fat biosynthesis [96]. Benzafibrate was shown to act on skeletal muscle inducing
PGC-1α gene expression in both cardiac and skeletal muscles from female mice and cultured
myocytes, functioning in a PPARδ-mediated fashion [44]. Table 1 summarizes some of the
pharmacological strategies used to increase PGC-1 and related mitochondrial content.
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Table 2 Summary of pharmacological stimulators of PGC-1 and mitochondrial biosynthesis in various
experimental models of skeletal muscle
Mitochondrial
Stimulators
AICAR

Experiment Model

Findings

Primary rat skeletal muscle

↑ PGC-1 mRNA [28, 30]

Mice (WT/PGC-1 KO)

↑ PGC-1, phospho-AMPK, GLUT4 transporter mRNA and protein [56]

L6 Myotubes

↑ CaMK, AMPK, COX1/4, PGC-1α protein [61]

Mice (WT/ Mutant AMPK-DN)

↑ PGC-1 isoform mRNA [103]

Rat skeletal muscle

↑ Mitochondrial enzymes and protein [119]

Metformin

Wistar rat skeletal muscle

↑ PGC-1α and phospho-AMPK protein [101]

GW501516

Mice with varied fat diets

FCCP/DNP

Fibroblasts and mice

↑ PGC-1α mRNA, phospho-AMPK and phospho-ERK protein and
AMP:ATP [5, 16]
↑ PGC-1 mRNA and protein, mitochondrial proteins, NRF, AMPK, CREB
[85]
↑ PGC-1 mRNA and protein, mitochondrial proteins, glycolytic/oxidative
metabolism [110]
↑ PGC-1 mRNA, phospho-Akt, cAMP [37]

β-2 adrenoceptor agonists
Rosiglitazone (TZD)

Pioglitazone (TZD)
Fibrates

Human rhabdomyosarcoma
cells
Wistar rat muscle and C57/BL6
male mice
C2C12 Mouse Myoblasts &
db/db mice
10 obese and 10 healthy
subjects
26 drug-naïve patients
Mouse skeletal/cardiac muscle
and C2C12/L6 myocytes

↑ PGC-1 mRNA /protein, mitochondrial mass [74]
↑ PGC-1, PPARβ/δ mRNA [63]
↑ PGC-1α/β, phospho-AMPK protein, and PPARα mRNA [15]
↑ PGC-1α, PPARβ/δ mRNA, PPRE activity [96]
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Dietary PGC-1 Stimulators
Unlike synthetic chemicals, which often possess significant toxicity and lethality, many dietary
constituents offer similar benefits with greatly reduced side effects. Commonly consumed central
nervous stimulants such as caffeine increase AMPK phosphorylation, as well as cAMP
accumulation which activates CREB ultimately leading to PGC-1 expression [19, 52, 61, 71, 72].
Caffeine also works by increasing intracellular Ca2+ leading to CaMK activation and subsequent
AMPK phosphorylation [19, 52, 61, 71, 72]. We previously demonstrated that both research
grade caffeine and dietary supplements containing stimulants can effectively induce PGC-1
resulting in greater mitochondrial content and oxidative capacity in skeletal muscle cells [110,
111]. Limited information regarding other dietary methyl-xanthines such as theophylline and
theobromine (found in tea and chocolate, respectively) have been shown to increase skeletal
muscle cAMP, one precursor to PGC-1 expression [55]. Additionally, selected xanthine
metabolites can increase calcium uptake and reduce cellular ATP content in rat-liver which are
known cellular precursors to increased PGC-1 expression leading to mitochondrial biosynthesis
[20]. Forskolin (found in the herb Coleus forskohlii), a common constituent of many over-thecounter dietary supplements is also proposed to function through a related mechanism by
increasing mitochondrial enzyme activity [18, 55]. Similar to caffeine, catecholamines (such as
epinephrine) which are released during intense exercise have been shown to increase PGC-1
expression in mouse and rat skeletal muscle and adipocytes [30, 100, 103]. β-2 adrenoceptor
agonists such as synephrine and ephedra also promote the formation of cAMP [23], although
there appears to be no direct evidence that either catecholamine-like compound increases PGC-1
expression or mitochondrial content. Green tea and black tea extracts are rich in polyphenols
such as epigallocatechin gallate (EGCG), which are proposed to increase effects of circulating
catecholamines through inhibition of catechin-O-methyl transferase [24, 42]. EGCG has been
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shown to significantly increase GLUT4 translocation in skeletal muscle of rats, as well as
increase glucose uptake and GLUT4 translocation in L6 myotubes [105]. Moreover, in high fatfed C57bl/6J mice, EGCG increased mRNA levels of several mitochondrial biosynthetic genes
including NRF-1 and UCP3 (downstream targets of PGC-1), as well as PPARα [88]. EGCG was
also shown to increase AMPK and p38MAPK phosphorylation which promotes PGC-1
phosphorylation and activation [21].
Poly-unsaturated fatty acids (PUFAs) are of great interest for metabolic and inflammatory
disease. Longer chain omega 3 fatty acids appear to stimulate PPRE activation by acting as direct
ligands for PPAR, thereby increasing association of RXR-PPAR leading to increased fatty acid
oxidation with decreased fatty acid biosynthesis [17, 96]. Eicosapentaenoic acid (EPA) and
tetradecylthioacetic acid (TTA) were shown to have a pronounced effect on PGC-1 expression,
fatty acid oxidation, and rodent body weight and composition [27, 59]. Male C57BL6 mice fed a
diet rich in fish oil (3.4% energy) display increased PPARα/γ expression along with PGC-1α,
NRF, and TFAM ultimately leading to increased mitochondrial mass and number in [54].
Additionally, combination EPA/DHA (docosahexaenoic acid) has been shown to reduce fat mass
in C57BL/6J mice, and DHA independently induced NRF-1 expression in a PGC-1 dependent
manner in 3T3-L1 adipocytes [27]. Moreover, we have recently shown that combination
EPA/DHA can increase mitochondrial content and function [109]. In addition to long-chain fatty
acids such as EPA and DHA, short chain fats such as butyric acid (found in cheese and butter)
have been shown to increase PGC-1 expression, as well as increase oxidative capacities in L6
myocytes and skeletal muscle of rodents [33].
Similar to select lipids and stimulants, the amino acid leucine has been shown to increase
mitochondrial content in both adipocytes and muscle cells [9, 98, 99]. In muscle, leucine
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increases SIRT1 phosphorylation, acting as a potent stimulator of both AMPK and PGC-1
activation [9, 98, 99]. It is speculated however, that the effects of leucine on protein synthesis
and total energy expenditure also indirectly lead to activation of AMPK by increased
consumption of ATP leading to increased mitochondrial content to support heightened energy
consumption [108]. Our group recently verified the effects of leucine treatment on PGC-1
expression with simultaneous increase in mitochondrial content using human and mouse cell
models [108]. Other nitrogen-containing compounds including arginine and arginine-like
metabolites, increase nitric oxide (NO) which stimulates the formation of cGMP and
cooperatively interacts with AMPK and CaMK leading to PGC-1 induction [31, 57].

In

adipocytes, arginine was shown to increase mitochondrial content in ambient temperatures, and
intensify cold-induced browning of adipocytes [77].
In addition to essential nutrients and amino acids, select phytochemicals (such as EGCG
described above) have become of great interest for treating/preventing chronic disease, including
diseases linked to mitochondrial malfunction. Resveratrol found in grapes, peanuts and most
famously in red wine was thought to activate SIRT1, which deacetylates PGC-1 and promotes
AMPK phosphorylation of PGC-1 and FOXO leading to PGC-1 activation and expression
thereby improving insulin sensitivity and cellular antioxidant status [6, 8, 53, 126]. Recently, it
has become unclear if resveratrol acts by directly activating SIRT or solely by activating AMPK
through indirect means to drive PGC-1 activation and expression; however, experiments
performed with SIRT1 knockout mice illustrate that resveratrol increases AMPK in a SIRT1
mediated fashion in skeletal muscle [6, 22, 78]. Resveratrol treatment appears to increase
expression and deacetylation of PGC-1 leading to significantly elevated mitochondrial DNA and
content which appears to function in part through AMPK activation and through increased SIRT
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expression [53, 126]. In muscle-specific SIRT1 knockout mice, resveratrol can still function to
increase mitochondria by activating existing PGC-1 protein [64]. In addition, supplementation
with resveratrol has been shown to improve many clinically meaningful characteristics including
circulating lipids, glucose, and inflammatory markers [104]. Despite some controversy regarding
the exact mechanism(s) of action, resveratrol appears to be a potent stimulator of PGC-1 and
mitochondrial biogenesis in skeletal muscle. Bruckbauer and colleagues evaluated the synergistic
effect of simultaneous leucine and resveratrol treatment of cultures 3T3 adipocytes and C2C12
myocytes and found that concurrent treatment significantly elevated SIRT1 and SIRT3 in both
cell models [10]. Additionally, they found that combination leucine and resveratrol increased
AMPK content and fatty acid oxidation under both high and low glucose in cultured adipocytes
[10].
Fucoxanthin, a chlorophyll-associated carotenoid component of chloroplasts found in sea weed
has also recently been shown to increase GLUT4 translocation of skeletal muscle in rodents
though activation of Akt and insulin receptor in part as a result of PGC-1 induction [69]. Lipoic
acid and ubiquinol (CoQ10) have been shown to increase nuclear PGC-1 levels with heightened
PPARγ activation, NRF-2, TFAM, and mitochondrial content in C2C12 mouse myoblasts [115].
Several experiments have shown that statin treatment reduces CoQ10 levels resulting in
mitochondrial dysfunction and possibly myopathy [1, 7]. Interestingly, our laboratory recently
demonstrated that concurrent statin and CoQ10 treatment rescues statin-induced metabolic
dysfunction in muscle cells [107]. Despite increasing interest in food chemicals and natural
products, the effects of many of the aforementioned components on metabolic gene expression
and molecular metabolism still remain unexplored. Although not an exhaustive list of all
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potential dietary metabolic stimulators, Table 2 summarizes some evidence supporting dietary
stimulation of PGC-1α and resulting mitochondrial biosynthesis.
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Table 3 Summary of dietary stimulators of PGC-1 and mitochondrial biosynthesis in various experimental
models of skeletal muscle
Mitochondrial
Stimulators
Caffeine

Experiment Model

Findings

Primary rat myoblasts

↑ PGC-1 mRNA [52]

Human rhabdomyosarcoma cells

↑ PGC-1 mRNA and protein, mitochondrial proteins, glycolytic/oxidative metabolism
[110]
↑ CaMK, AMPK, COX1/4, PGC-1α protein [61]

L6 Myotubes

Xanthine
Metabolites

Rat myotubes

↑ AMPK, COX-1, cytosolic Ca2+, mitochondrial enzymes, fatty acid
oxidation↑PGC-1 protein, COX, CytC, NRF-1/2, tFAM cytosolic Ca2+ [71-73]
↑ cAMP and mitochondrial enzymes/activity [55]

Rat hepatocytes

↓ Mitchondrial ATP [20]

Forskolin

Rat myotubes

↑ cAMP and mitochondrial enzymes/activity [55]

Human myotubes

↑ Mitochondrial content [18]

Primary rat skeletal muscle

↑ PGC-1mRNA [30]

Rat adipose tissue

↑ PGC-1 mRNA [100]

Mice (WT/ Mutant α1-AMPKDN)
Rat muscle and L6 myotubes

Activates β-2 receptors, ↑PGC-1 isoform mRNA [103]

C57bl/6J mice

↑ NRF-1 UCP3, and PPARα mRNA [88]

C2C12 myoblasts

↑ phospho-AMPK and phospho-38MAPK [21]

Mice adipose tissue

↑ PGC-1 and NRF-1 mRNA, mitochondrial proteins, fatty acid oxidation ↑ fatty acid
oxidation, mitochondrial content, ↓ plasma TAGs [27]
↑ PPARα/γ, PGC-1α, NRF, and TFAM expression, and total mitochondrial mass [54]

L6 Myotubes

Catecholamines

Green Tea
(EGCG)

EPA/DHA

Male C57BL6 mice

↑ GLUT4 translocation [105]

C2C12 myoblasts

↑ PGC-1 mRNA and protein, mitochondrial proteins, glycolytic/oxidative metabolism
[109]
↑ PGC-1 and AKT mRNA and protein, AMPK and p38 activity, muscle fiber type
[33]
↑ PGC-1 and NRF mRNA and protein, mitochondrial proteins, mitochondrial
staining, oxidative metabolism [98, 99]
↑ SIRT activation, ↑NRF and UCP RNA [9]

Human rhabdomyosarcoma cells
& C2C12 myoblasts
C2C12 myoblasts and L6

↑ PGC-1 and cytochrome C protein, mitochondrial proteins, glycolytic/oxidative
metabolism with altered ATP production [108]
↑ AMPK protein, ↑ PGC-1 mRNA [57]

C2C12 myoblasts and L6

↑ cGMP, AMPK, and CaMK [77]

Zucker rats

↑ AMPK, CaMK, PGC-1 mRNA in adipose [31]

C57Bl/6J and KKAy mice

↑ PGC-1, ERR, SIRT, oxygen consumption [6, 53]

Catch-up growth mice

Rescued loss mitochondrial function and PGC-1 expression [126]

Adult-Inducible SIRT1 Knockout
Mice
Muscle-specific SIRT-knockout
mice and C2C12 myoblasts
10 Healthy obese males

↑ PGC-1α/β, NRF, TFB, TFAM, AMPK, and SIRT expression with ↑ mitochondrial
content through multiple mechanism dependent on dose [78]
↑ PGC-1α, phospho-AMPK, and SIRT expression with ↑PGC-1α activity and ↑
mitochondrial content [64]
↑ PGC-1 and phospho-AMPK protein [104]

Fucoxanthin

KKAy mice

↑ PGC-1 and AKT phosphorylation [69]

Lipoic
Acid/CoQ10

C2C12 myoblasts

↑ PGC-1, TFAM and NRF mRNA [115]

Human rhabdomyosarcoma cells
Butyrate

C57BL/6 mice

Leucine

C2C12 myoblasts and adipocytes

Arginine/Nitric
Oxide Donors

Resveratrol
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Downstream PGC-1α Effects
As previously mentioned, PGC-1α modifies metabolic rate and expression of genes involved in
metabolism, fat oxidation and mitochondrial biosynthesis [80, 112, 125]. PGC-1α is also an
important signaling molecule in the activation and regulation of gluconeogenesis, which is likely
mediated through FOXO1 and ERR-α [2, 41, 84, 95, 125]. Further evidence suggests that an
increase in PGC-1α can improve insulin sensitivity and improve muscle function. It has also
been identified that PGC-1α is essential for the recovery from the diminished ATP caused by
chemical uncoupling as evidenced by the lack of recovery in PGC-1α null cells and animals [85].
PGC-1α induction and mitochondrial biosynthesis are usually stimulated by heightened energy
needs which require increased nutrient uptake. Enhanced expression of PGC-1β leads to
corresponding increases in components that facilitate fatty acid oxidation including carnitine acyl
transferase and fatty-acyl dehydrogenases, demonstrated in C2C12 myocytes [29, 32]. In
addition to increases in fatty acid oxidative components, PGC-1 also increases expression of
GLUT transporters namely GLUT4 to facilitate increased glucose uptake and metabolism [56,
109]. PGC-1 induction can also increase expression of mitochondrial uncoupling proteins which
enhance total cellular energy expenditure [29]. Ectopic PGC-1 expression has also been linked to
increased skeletal muscle angiogenesis through induction of VEGF via ERR activation
independent of HIF in skeletal muscle myocytes and in vivo [86]. These observations are
contrary to previous hypotheses that PGC-1 functions to control oxygen availability through a
coupling with HIF-1 [4, 70]. This information supports the hypothesis that chronic PGC-1
activation leads to increased oxidative capacity through heightened oxygen availability which
supports increases in mitochondria and oxidative components. Figure 2 summarizes many
previously mentioned dietary stimulators of mitochondrial biosynthesis with proposed
mechanisms of action and several downstream effects.
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Fig 3 Summary of documented dietary stimulators of PGC-1 and related nuclear factors leading to increased
mitochondrial biosynthesis and other metabolic events
Notes: short dashed line indicates mobilization to the nucleus leading to altered metabolic gene expression. Long
dashed line indicates poly-unsaturated fats act as ligands for the PPAR/RXR heterodimer.
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Concluding Remarks
Clinically, the relationship between low PGC-1α expression and several metabolic diseases
including type II diabetes/obesity and neurological disease has been identified [14, 76, 79, 94,
124]. Patients with early onset of type II diabetes express constitutively lower levels of skeletal
muscle PGC-1α [40]. Low PGC-1α is also associated with reduced expression of oxidative
phosphorylation genes, decreasing fatty acid oxidation and energy utilization [66, 76, 92]. These
observations and others support the hypothesis that mitochondrial biogenesis mediated through
pharmacological or metabolic induction of the PGC-1α pathway is likely to be an effective
therapeutic intervention for many disorders [118].
Current research has outlined many dietary factors that can increase both PGC-1α expression and
the resulting increase in oxidative capacity. Much of the current literature is somewhat limited as
a result of inferred increases in mitochondrial content/activity rather than direct measurement. In
much of the preliminary work, only PGC-1 or related protein (or RNA) was measured and
increased mitochondrial content was then inferred as an inevitable downstream effect. Improved
understanding of energy dynamics combined with advances in technology has led to substantial
improvements in current methods for quantifying mitochondrial biosynthesis (techniques which
are reviewed elsewhere) [62]. Additionally, little is known about the translation from in vitro and
animal models to therapeutic interventions in humans. Several questions come to mind. Are
experimental doses practical and achievable from food or supplement? Is the functional food
chemical altered once absorbed through the gut, and if so, how many functional analogs may
exists? Will combinations of PGC-1 stimulators act synergistically, in a saturable way, or oppose
one another? Further investigation is required to answer these, and many other questions
pertaining to the potential efficacy of dietary PGC-1 stimulator for metabolic disease. Figure 2
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and Table 2 describes the significant findings and conclusions of the literature summarized in
this review.
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Abstract
Background: Obesity is an increasingly prevalent and preventable morbidity with multiple
behavioral, surgical and pharmacological interventions currently available. Commercially
available dietary supplements are often advertised to stimulate metabolism and cause rapid
weight and/or fat loss, although few well controlled studies have demonstrated such effects. Our
work uniquely describes the effects of a commercially available dietary supplement on resting
metabolic rate in humans as well as the metabolic and biochemical effects in vitro. Methods:
Human rhabdomyosarcoma cells (RD) and mouse myoblasts (C2C12) were cultured under
standard conditions and treated with various doses of a commercially available supplement (RF)
for various durations and assessed for changes in metabolism, metabolic gene expression and
mitochondrial content. Additionally, human subjects ingested either placebo or RF in a doubleblind placebo controlled fashion and metabolic rate and blood pressure were measured at 3 time
points for 3 hours post-ingestion. Results: RF enhanced metabolism, metabolic gene expression,
and mitochondrial content in both cell models. RF also enhanced energy expenditure in human
male subjects without altering substrate utilization. RF also significantly increased systolic blood
pressure. Conclusion: RF appears to increase metabolism immediately following ingestion,
although additional research is needed to examine safety and efficacy for human weight loss.

Key Words: Obesity, Fat Burners, Resting Energy Expenditure, Mitochondrial Biogenesis

51

Background
Obesity is an increasingly prevalent morbidity with nearly two thirds of adult Americans
overweight, and over 32% of men and 35% of adult women clinically obese [1]. It is forecasted
that roughly 85% of adult Americans will be overweight, over half of which will be clinically
obese by 2030 [2, 3]. Over the past decade, chemical and behavioral interventions that favorably
modify metabolic rate have been central to obesity research. Several over-the-counter dietary
supplements claim to increase metabolic rate and enhance fatty acid catabolism. Of the available
over-the-counter dietary supplements, Ripped Freak® (RF) produced by PharmaFreak is
purported to increase metabolic rate and fat metabolism.
Caffeine has been documented to increase metabolic rate in humans and in cell culture [4-10].
Human data suggests that caffeine elicits a dose-dependent increase in resting metabolic rate [9].
In addition, dietary components (such as green tea) have been shown to increase metabolism
more effectively than caffeine alone [4]. Dietary supplements similar to RF were previously
shown to increase markers of fat mobilization, metabolic rate (measured via indirect
calorimetry), and reduce bodyweight and body fat (estimated via Dual-energy X-ray
absorptiometry) in healthy young subjects following ingestion [11-18]. Our laboratory recently
identified that treatment of cultured skeletal muscle with caffeine can increase both metabolic
rate and mitochondrial content in muscle cells suggesting that commercially available metabolic
stimulators might have similar effects [8]. Caffeine is believed to work through
phosphodiesterase inhibition leading to increases in cAMP or through increasing cytosolic Ca2+
[8, 19, 20]. In addition, our lab recently showed that treatment with either of two similar overthe-counter supplements, or several other dietary components lead to increased metabolic rate
and mitochondrial content in skeletal muscle cells [8, 21-24]. We demonstrated along with others
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that stimulation of metabolism by dietary components induces many molecular adaptations
including metabolic gene expression. Specifically, expression of peroxisome proliferatoractivated receptor γ coactivator-1α (PGC-1α) is increased following administration of various
dietary stimulators of metabolism [8, 22-24]. PGC-1α acts as a transcriptional coactivator that is
essential for mitochondrial biosynthesis and acts as a master regulator of energy homeostasis and
metabolism [25-27]. Our group has previously reviewed the potential role for dietary
components in the stimulation of PGC-1α and corresponding favorable metabolic adaptations for
benefit in metabolic disease [28].
RF is a newer dietary supplement which has limited research regarding safety or efficacy. RF is
advertised to increase metabolic rate, oxygen consumption, and fatty acid oxidation. RF is also
purported to modify signal transduction and induction of genes that control energy homeostasis.
Several of the ingredients purportedly comprising RF’s proprietary blend including caffeine,
green tea, raspberry ketones, and capsaicin have been previously linked to increased metabolic
rate (Table 1). These ingredients are regularly promoted by vendors and figureheads of
mainstream media, often without any supporting evidence of efficacy. Moreover, because
supplements commonly contain a variety of ingredients in proprietary blend forms, and few
controlled studies have been performed to address the metabolic effects at the cellular level,
further work is needed to identify possible metabolic effects. This work seeks to evaluate the
short term effects of RF treatment on metabolic characteristics in cultured muscle cells.
Additionally, we investigated the effects of RF consumption on resting metabolic rate in healthy
male volunteers.
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Table 4 Purported composition of Ripped Freak®. *percent daily value not established
RIPPED FREAK® FORMULA 766.6 mg *
FAT BURNING METABOLISM AMPLIFIER 400mg *
Methyl EGCG™ (EGCG Derivative Stack) (Green Tea Extract/Camellia Sinensis)
-Epigallocatechin-3-O-(3-O-Methyl) gallate Ester (EGCG 3' 'Me)
-Epigallocatechin-3-O-(4-O-Methyl) gallate Ester (EGCG 4' 'Me)
-4'-O-Methyl-Epigallocatechin-3-O-Gallate Ester (EGCG 4'Me)
-Epigallocatechin-3-O-(3,4-O-Methyl) gallate Ester(EGCG 3' '4' 'diMe)
-4'-O-Methyl-Epigallocatechin-3-O-(4-O-Methyl) gallate Ester (EGCG 4'4' 'diMe)
Oleuropein Aglycone (Olive Leaf Extract/Olea Europaea )
1,3,7-Trimethyl-1H-Purine-2,6(3H,7H)-Dione Methyl Gallate Ester
(Caffeine) (Coffee/Coffea Arabica, Whole Bean)
UNCOUPLING PROTEIN / OXYGEN UTILIZATION AMPLIFIER 200mg *
CH-19 Sweet Red Pepper Ester Stack
(CH-19 Sweet Red Pepper Extract/Capsicum Annum, Fruit) (0.75% Capsiate)
4-Hydroxy-3-Methoxybenzyl (E)-8-Methyl-6-Nonenoate Ester
4-Hydroxy-3-Methoxybenzyl 8-Methyl-Nonanoate Ester
4-Hydroxy-3-Methoxybenzyl 7-Methyl-Octanoate Ester
HORMONE SENSITIVE LIPASE FAT MOBILIZATION AMPLIFIER 166.6mg *
4-(4-Hydroxyphenyl)-2-Methyl Ethyl Ketone (Raspberry Ketone)
4-(4-Hydroxyphenyl)-2-Butanone Methyl Gallate Ester (Raspberry Ketone - Gallic Acid)
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Methods
Cell Culture- Human rhabdomyosarcoma cells (RD) and mouse myoblasts (C2C12) were
purchased from ATCC (Manassas, VA). Cells were cultured in Dulbecco’s Modified Eagle’s
Medium (DMEM) containing 4500mg/L glucose and supplemented with 10 % heat-inactivated
fetal bovine serum (FBS) and 100U/mL penicillin/streptomycin, in a humidified 5% CO2
atmosphere at 37°C. Stock Ripped Freak® (RF) from PharmaFreak was purchased over the
counter and was diluted to various concentrations in ethanol; doses for RD cells contained 200
µg/ml or 100 µg/ml and doses for C2C12 cells contained 20 µg/ml or 10 µg/ml all of which were
determined through pilot data to preserve cell viability. Cells were treated for various durations
with final concentration of ethanol 0.1% for all treatments which did not alter cell viability
(Supplemental Figure 1).
Metabolic Assay- Cells were seeded overnight in 24-well culture plate from SeaHorse
Bioscience (Billerica, MA) at density 5 x 105 cells/well (RD cells) or 3 x 105 cells/well (C2C12
cells), treated and incubated for 3 or 6 hours as described above. Following treatment, culture
media was removed and replaced with XF Assay Media from SeaHorse Bioscience (Billerica,
MA) containing 4500mg/L glucose free of CO2 and incubated at 37°C. Per manufactures’
protocol, SeaHorse injection ports were loaded with oligomycin, an inhibitor of ATP synthase
which induces maximal glycolytic metabolism and reveals endogenous proton leak
(mitochondrial uncoupling) at a final concentration 1.0 µM. Oligomycin addition was followed
by the addition of carbonyl cyanide p-[trifluoromethoxy]-phenyl-hydrazone (FCCP), an
uncoupler of electron transport that induces peak oxygen consumption (an indirect indicator of
peak oxidative metabolism) at final concentration 1.25 µM. Rotenone was then added in 1.0 µM
final concentration to reveal non-mitochondrial respiration and end the metabolic reactions [29,
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30]. Extracellular acidification, an indirect measure of glycolytic capacity, and oxygen
consumption, a measure of oxidative metabolism was measured using the SeaHorse XF24
Extracellular Analyzer from SeaHorse Bioscience (Billerica, MA). SeaHorse XF24 Extracellular
Analyzer was run using 8 minute cyclic protocol commands (mix for 3 minutes, let stand 2
minutes, and measure for 3 minutes) in triplicate.
Cellular ATP Content- Cells were seeded overnight in a 6-well plate at density 1 x 106 cells/well
and treated as described above for 24 hours. The cells were lysed in 1% CHAPS lysis buffer
from Chemicon (Billerica, MA) in PBS with Ca2+ and MG2+ and the ATP-containing supernatant
was recovered. Samples were allocated into a 96-well plate with a 1:1 dilution of ATP
Bioluminescence Reagent from Sigma (St. Louis, MO) with a 100 µM final volume and
luminescence was measured and normalized to serial dilutions of ATP. ATP concentrations were
normalized to cell density determined through hemocytometey measured by staining cells with
trypan blue from Sigma (St Louis, MO) with cell density estimated using a Countess TM cell
quantification system from Invitrogen (Carlsbad, CA).
Quantitative Real Time Polymerase Chain Reaction (qRT-PCR)- Following treatment and
incubation as described above, the total RNA was extracted using RNeasy Kit from Qiagen
(Valencia, CA), per manufacturer’s protocol. Total RNA was quantified by Nanodrop
spectrophotometry. cDNA was synthesized from 5000 ng total RNA using the Retroscript™ RT
kit from Ambion (Austin, TX) according to manufacturer’s instructions. PCR primers were
designed using Primer Express software from Invitrogen (Carlsbad, CA) and synthesized by
Integrated DNA Technologies (Coralville, IA). Amplification of PGC-1α, nuclear respiratory
factor (NRF-1), mitochondrial transcription factor A (TFAM), and glucose transporter 4
(GLUT4) were normalized to the housekeeping gene, TATA Binding Protein (TBP). Table 2
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summarizes the forward and reverse primers of each gene. qRT-PCR reactions were performed
in triplicate using the LightCycler 480 real-time PCR system from Roche Applied Science,
(Indianapolis, IN). SYBR Green based PCR was performed in triplicate using 5000 ng of cDNA
per sample; final primer concentrations were 10 µM in a total volume of 30 µl. The following
cycling parameters were used: 95˚C for 10 minutes followed by 45 cycles of 95˚C for 15
seconds, and 60˚C for one minute. Relative expression levels were determined by the ΔΔCp
method and compared to the lowest expressing group as previously described [31].
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Table 5 Summary of qRT-PCR primers from Integrated DNA Technologies (Coralville, IA). Abbreviations:
peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1α), nuclear respiratory factor
1 (NRF-1), mitochondrial transcription factor A (TFAM), and glucose transporter 4 (GLUT4) and TATA
binding protein (TBP). H indicates for primers for human RNA and M indicates primers for mouse RNA.
Primer Name

Forward Sequence

Reverse Sequence

TBPH

5’-CACGAACCACGGCACTGATT-3’

5’-TTTTCTTGCTGCCAGTCTGGAC-3’

PGC-1αH

5’-ACCAAACCCACAGAGAACAG-3’

5’-GGGTCAGAGGAAGAGATAAAGTTG-3’

NRF-1H

5'-GTATCTCACCCTCCAAACCTAAC-3'

5'-CCAGGATCATGCTCTTGTACTT-3'

TFAMH

5'-GGGAAGGAGGGTTGTGTATTT-3'

5'-AGGAGTTAGCCAAACGCAATA-3'

GLUT4H

5'-AAGAATCCCTGCAGCCTGGTAGAA-3'

5'-CCACGGCCAAACCACAACACATAA-3'

TBPM

5’-GGGATTCAGGAAGACCACATA-3’

5’-CCTCACCAACTGTACCATCAG-3’

PGC-1αM

5'-GACAATCCCGAAGACACTACAG-3'

5'-AGAGAGGAGAGAGAGAGAGAGA

NRF-1M

5'-ACCCTCAGTCTCACGACTAT-3'

5'-GAACACTCCTCAGACCCTTAAC-3'

TFAMM

5'-GAAGGGAATGGGAAAGGTAGAG-3'

5'-ACAGGACATGGAAAGCAGATTA-3'

GLUT4M

5'-GGAGGGAGCCTTTGGTATTT-3'

5'-CAGGCGAGGACACTCATCTT-3'
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Flow Cytometry- Cells were plated in 6-well plates at a density of 1.0 x 106 cells/well treated in
triplicate and incubated as previously described above for 24 hours. Following treatment, the
media was removed and the cells were re-suspended in pre-warmed media with 200 nM
Mitotracker Green from Life Technologies (Carlsbad, CA) and incubated for 45 minutes in a
humidified 5% CO2 atmosphere at 37°C. The cells were pelleted, the media with Mitotracker
was removed and the cells were suspended in pre-warmed media. Group mean fluorescence was
measured using Facscalibur filtering 488nm. To quantify PGC-1α expression, we used
immuonofluorescent staining measured by flow cytometry. Cells were permeabilized with PBS
with 0.1% Tween from Sigma (St. Louis, MO) for 10 minutes and blocked for 1 hour with PBS
with 0.1% Tween and 3.0% BSA from Sigma (St. Louis, MO). Cells were stained with either an
anti-PGC-1α primary polyclonal antibody from Santa Cruz Biotechnologies (Santa Cruz, CA) at
1:200 dilution in PBS with 0.1% BSA overnight. The cells were rinsed with PBS with 0.1%
Triton 100X and 3.0% BSA, and secondary anti-rabbit AlexFluor 488 antibody from Invitrogen
(Carlsbad, CA) was applied in 1:200 dilutions. Cells were rinsed thoroughly and fluorescence
was measured via flow cytometry.
Microscopy and Immunofluorescence- Chamber-slides from BD Bioscience (Sparks, MD),
were seeded with 5000 cells/well. To verify PGC-1α protein expression, cells were cultured and
treated for 24 hours as described above. Cells were fixed using 3.7% formaldehyde in media,
permeabilized with PBS with 0.1% Triton 100X from Sigma (St. Louis, MO) for 10 minutes and
blocked for 1 hour with PBS with 0.1% Triton 100X and 3.0% BSA from Sigma (St. Louis,
MO). Cells were stained with an anti-PGC-1α primary polyclonal antibody from Santa Cruz
Biotechnologies (Santa Cruz, CA) at 1:200 dilution in PBS with 0.1% BSA overnight. The cells
were rinsed with PBS with 0.1% Triton 100X and 3.0% BSA, and secondary anti-rabbit
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AlexFluor 633 antibody from Invitrogen (Carlsbad, CA) was applied in 1:200 dilution. Slides
were mounted with Prolong Gold with DAPI from Invitrogen (Carlsbad, CA) and cured
overnight. Cells were imaged using the Axiovert 25 microscope with AxioCam MRc from Zeiss
(Thornwood, NY). To verify increased mitochondrial content, the cells were then stained with
Mitotracker 200 nM from Invitrogen (Carlsbad, CA) for 45 minutes, and fixed in 3.7%
formaldehyde in pre-warmed media. Cells were mounted, cured and imaged as described above.
Cell Viability- Cells were seeded in 96-well plates at density 5,000 cells/well and grown over
night. Cells were treated and incubated as previously described for 24 hours. Media and
treatment were removed and media containing 10% WST1 was added to each well and were
incubated as previously described. Fluorescence was measured 1 hour following WST1 addition
using Wallac Victor3V 1420 Multilabel Counter from PerkinElmer (Waltham, MA).
Human Subjects- Healthy male volunteers aged 18-40 years old were eligible for the study.
Participants were excluded if they were caffeine naïve, clinically obese (BMI > 30 kg/m 2), if
they had known cardiovascular disease, hypertension, or refused to adhere to subject-study
procedures. Participants were kindly asked to abstain from caffeine and/or dietary supplement
consumption in addition to rigorous exercise at least 48 hours prior to each measurement.
Participants were also asked not to smoke at least 12 hours prior to each measure. Subject food
intake was recorded the day prior to initial metabolic measurements, and subjects were asked to
consume approximately the same meal composition 24 hours prior to the second measurement.
Subjects completed a health history questionnaire, food and beverage recall, and informed
consent IRB #13-066. Participants reported the usual number of caffeinated beverages (coffee,
tea, soft drink, energy drink, etc.) with corresponding serving size, and were asked to list other
regularly consumed stimulants (such as those found in dietary supplements or over the counter
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medications). Subject height, weight, and resting blood pressure were recorded prior to initial
metabolic measurement. Body composition was estimated by 3 site skin-fold measurements
(chest, abdominal, and thigh) and estimated body density was used to calculate body fat percent
using the Siri equation. Descriptive subject data are listed in Table 3.
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Table 6 Summary of subject anthropometric variables and estimated caffeine consumption. † Body fat
percent was estimated using 3 site skin fold as described in methods estimated using ExRx body fat
calculator. ‡ Caffeine intake was estimated through 24 hour recall food questionnaire and caffeine content of
food and beverage list published by the Mayo Clinic available at:
http://www.mayoclinic.com/print/caffeine/AN01211/METHOD=print
Subject Variable

Average (±SD)

Age (years)

26.7 (±3.86)

Weight (kg)

77.75 (±8.56)

Height (cm)

175 (±5.0)

2

BMI (kg/m )

25.34 (±2.65)

Body Fat (%) †

14.78 (±6.7)

Lean Body Mass (kg)

65.97 (±6.05)

Caffeine Consumption (mg/day)‡

292.45 (±150.76)
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Human Metabolic Measurements- Each subject was asked to participate in 2 double-blinded
trials (one placebo filled with dextrose and one RF-treated) resting energy expenditure with at
least 48 hours between the two measurements. Treatments were provided in a double-blind
fashion by a third party. Following anthropometric measurements, the subject was asked to
consume a blinded treatment which was followed by a resting blood pressure measurement.
Metabolic measurements were taken at baseline, and both one and two hours following treatment
ingestion with blood pressure taken prior to each metabolic measurement. Resting energy
expenditure (REE) and respiratory exchange ratio (RER) were measured using a TrueOne 2400
metabolic measurement system from ParvoMedics (Sandy, UT) following overnight fast similar
to previous reports [16]. The ParvoMedics metabolic cart was calibrated daily per manufacturer
guidelines prior to each trial. Participants rested in a supine position in a comfortable ambient
temperature in a quiet and dark room. Expired gas was collected by placing a clear hood over the
participant’s head and upper torso area with plastic seal secured under the subject. Data were
collected for approximately 30 minutes per measurement and the 5 minute duration which
produced the lowest variability of REE data was used for values of REE and RER for all tests.
REE data was transformed into kcals/kg/day for both total body weight and lean body mass.
Flow rate was monitored by a designated research assistant during the course of the test and
maintained at a rate of 1–1.2% expired carbon dioxide per manufacture’s protocol.

Statistical Analysis- Cellular metabolic assays, metabolic gene expression, flow cytometry, and
cell viability were analyzed using ANOVA with Dunnett’s post hoc test and pairwise
comparisons were used to compare treatments with control. Microscopy was analyzed using
student’s t test. Human REE (kcals/kg/day), RER (VCO2/VO2), and both systolic and diastolic
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blood pressure response were analyzed using paired t-tests for each time point and trial averages.
Correlations between age, BMI, and self-reported caffeine consumptions were analyzed using
linear regression. Values of p < 0.05 indicated statistical significance in all tests and Prism from
GraphPad (La Jolla, CA) was used to perform all statistical analyses.

Results
RF Enhances Oxidative Metabolism In Vitro- To evaluate the effects of RF treatment on
oxidative metabolism in cultured myocytes, we measured oxygen consumption. Treatment with
RF for either 3 or 6 hours significantly increased basal oxygen consumption in both cell models
(Figure 1A). Peak oxidative metabolism was also significantly increased in both cell models
following 3 hours of treatment, but was only significantly elevated in the C2C12 cell model
following 6 hours of treatment suggesting a differing response between the models with timedependence (Figure 1B). In correspondence with basal oxidative metabolism, cells treated with
RF also exhibited significantly greater mitochondrial uncoupling (proton leak) (Figure 1C).
RF Alters Glycolytic Metabolism and Metabolic Reliance In Vitro- To investigate the effects of
RF treatment on glycolytic metabolism, we measured extracellular acidification rate.
Interestingly, RF-treated RD cells either displayed no change or a reduced glycolytic rate while
RF-treated C2C12 cells exhibited a significant increase in basal glycolysis compared with
corresponding controls (Figure 1D). This discrepancy between the two cell models was also seen
during chemically induced peak glycolysis. Specifically, RD cells treated with RF exhibited
significantly reduced glycolysis at both 3 and 6 hours. Conversely, C2C12 cells treated with RF
showed significantly elevated peak glycolytic metabolism (Figure 1E). Because cells were
culture in high-glucose media (per ATCC recommendations), and because RD cells exhibited a
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dynamic increase in oxidative metabolism, we interpret the reduction in cellular acidification to
indicate more complete carbohydrate metabolism which we have previously described [24].
Despite discrepancy in glycolytic response between the 2 cell models, both cell types exhibited a
significantly increased reliance on oxidative metabolism (expressed as a ratio of OCR:ECAR)
when compared with respective controls (Figure 1F).
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Figure 4 Oxidative Metabolism (A) Basal oxidative metabolism indicated by oxygen consumption rate (OCR)
of RD (left) cells treated with either ethanol control or RF at 100 µg/ml or 200 µg/ml for 3 or 6 hours and
C2C12 (right) cells treated with either ethanol control or RF at 10 µg/ml or 20 µg/ml for 3 or 6 hours. (B)
Peak OCR of RD and C2C12 cells following addition of oligomycin following treatment as described in A. (C)
Mitochondrial uncoupling (endogenous mitochondrial proton leak) of RD and C2C12 cells treated as
described in A. (D) Basal glycolytic metabolism indicated by extracellular acidification rate (ECAR) of RD
(left) cells treated as described above. (E) Peak ECAR of RD and C2C12 cells following the addition of
oligomycin following treatment as described above. (F) Metabolic reliance expressed as a ratio of
OCR:ECAR.
NOTES: * indicates p < 0.05, ** indicates p < 0.01, and *** indicates p < 0.001 compared with control.
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RF Induces Metabolic Gene Expression In Vitro- To investigate the effects of RF treatment on
metabolic gene expression, we measured relative RNA expression of PGC-1α, NRF-1, TFAM,
and GLUT4 expression normalized to TBP following treatment with RF for 4, 12, and 24 hours.
RD cells treated with RF exhibited significantly elevated PGC-1α expression at initial time
points (Figure 2A) while C2C12 cells only exhibited elevated PGC-1α expression following 4
hours of treatment (Figure 2B). NRF-1 and TFAM, downstream targets of PGC-1α were also
significantly induced by RF after treatment of both cell models. Additionally, GLUT4 expression
was also elevated above control levels at various time points for both cell models the most
notable of which occurred at 24 hours.
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Figure 5 Metabolic Gene Expression. (A) Gene expression of RD cells treated with either ethanol control or
RF at 100 µg/ml or 200 µg/ml for 4, 12, or 24 hours of PGC-1α, NRF-1, TFAM, and GLUT4. (B) Gene
expression of C2C12 cells treated with either ethanol control or RF at 10 µg/ml or 20 µg/ml for 4, 12, or 24
hours of PGC-1α, NRF-1, TFAM, and GLUT4.
NOTES: * indicates p < 0.05, ** indicates p < 0.01, and *** indicates p < 0.001 compared with control.
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RF Induces Mitochondrial Biosynthesis Through PGC-1α- In order to assess changes in
metabolic gene expression, we quantified PGC-1α expression by flow cytometry. RF treatment
of RD cells significantly induced PGC-1α protein expression in a dose-dependent manner
compared with the control (Figure 3A). C2C12 cells treated with RF also displayed amplified
PGC-1α expression (Figure 3B). To verify our flow cytometry observations, we measured PGC1α protein expression by immunofluorescent confocal microscopy (Figure 3C and D,
respectively). Additionally, heightened PGC-1α expression in RF treated cells was also
associated with significantly elevated mitochondrial content in both cell models (Figure 4A and
B). In order to verify flow cytometry observations in both RD and C2C12 cells, we measured
mitochondrial content by immunofluorescent via confocal microscopy (Figure 4C and D,
respectively). In addition, RF treatment caused a significant reduction in cellular ATP content for
C2C12 myocytes without altering ATP content of RD cells (Figure 4E).
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Figure 6 PGC-1α Protein Expression (A) Group mean log fluorescence from flow cytometry of RD (left) and
C2C12 cells (right) treated as described in methods for 24 hours stained with PGC-1α primary antibody and
AlexaFluor 488 secondary antibody. (B) Group mean log fluorescence of confocal microscopy of RD cells
treated as previously described for 24 hours. (C and D) Representative images from fluorescent confocal
microscopy of RD cells (C) and C2C12 cells (D) treated as described earlier. Fluorescent measurements were
performed using N = 7 cells/treatment which were stained with PGC-1α primary antibody and AlexaFluor
533 secondary antibody (red) and DAPI (blue).
NOTES: * indicates p < 0.05, ** indicates p < 0.01, and *** indicates p < 0.001 compared with control. White
measurement bar represents 50 µm.
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Figure 7 Mitochondrial Content (A) Group mean log fluorescence from flow cytometry of RD (left) and
C2C12 cells (right) treated as described in methods for 24 hours stained with mitotacker green. (B) Group
mean log fluorescence of confocal microscopy of RD cells treated as previously described for 24 hours. (C and
D) Representative images from fluorescent confocal microscopy of RD cells (C) and C2C12 cells (D) treated
as described above. Fluorescent measurements were performed using N = 7 cells/treatment which were
stained with mitotracker (green) and DAPI (blue). (E) Cellular ATP content following treatment of either RD
cells (left) or C2C12 cells (right) with RF at various doses for 24 hours.
NOTES: * indicates p < 0.05, ** indicates p < 0.01, and *** indicates p < 0.001 compared with control. White
measurement bar represents 50 µm.
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RF Enhances Resting Energy Expenditure In Vivo- To evaluate the effects of RF consumption
on metabolic rate in humans, we measured REE following ingestion of either placebo or a single
serving of RF (in a double-blinded fashion). RF increased REE during initial measurement, and 1
and 2 hours post ingestion as well as average energy expenditure for the entire trial compared
with the control treatment (Figure 5A). RF consumption was associated with an average increase
in daily REE of 159.7 ±89.7 kcal/day. Unexpectedly, RER remained unchanged throughout the
trial between RF and placebo treatment (Figure 5B). To investigate the contribution of subject
variables (summarized in Table 1) on response to RF, we assessed relationships between age,
BMI, and prior self-reported caffeine consumption, none of which were significantly correlated
with RF response (Figure 6A, B, and C, respectively). Additionally, we measured the effects of
RF consumption on resting blood pressure. RF treatment elevated systolic blood pressure 2 hours
following ingestion, as well as the average systolic blood of subjects throughout the trial (Figure
6D). Diastolic blood pressure remained unchanged for each time point and for the average of the
trial (Figure 6E).
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Figure 8 Metabolic Rate and Substrate Utilization (A) Resting energy expenditure (REE) of human male
subjects following ingestion of either a placebo (control) or a single serving of RF. (B) Respiratory exchange
ratio (RER) of human male subjects following ingestion of either a placebo (control) or a single serving of RF.
NOTES: * indicates p < 0.05, ** indicates p < 0.01, and *** indicates p < 0.001 compared with control.
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Figure 9 Correlation of Subject Variables and Metabolic Response (A-C) Change in resting energy
expenditure (REE) of human male subjects following ingestion of either a placebo (control) or a single serving
of RF correlated with caffeine consumption, age, or BMI, respectively. (D) Systolic blood pressure of human
male subjects following ingestion of either a placebo (control) or a single serving of RF. (E) Diastolic blood
pressure of human male subjects following ingestion of either a placebo (control) or a single serving of RF.
NOTES: * indicates p < 0.05, ** indicates p < 0.01, and *** indicates p < 0.001 compared with control.
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Discussion
Previously, published data was scarce regarding the effects of RF on metabolism. Our data are
among the first observations to describe both the molecular and physiological effects of RF
which include increased cellular metabolism with enhanced mitochondrial uncoupling in vitro.
Interestingly, our observations demonstrate that RF treated muscle cells consistently exhibited
significantly greater basal oxidative accompanied by a significant increase in peak oxidative
capacity. Our data also demonstrates that 24 hour treatment with RF significantly induced PGC1α protein which was also accompanied by a significant increase in mitochondrial content in
both cell models. An interesting finding is that RD cells tolerated ten times higher treatments
than the non-malignant myoblasts, suggesting that RD cells are substantially more resilient. This
alteration in glycolytic metabolism may also be a result of the cancerous phenotype that RD cells
possess, which selectively prefer glycolytic metabolism. Additionally, in many cases the lower
dose tested in both cell models elicited an enhanced response over the highest dose tested
suggesting an optimal and saturable effect in vitro. Cumulatively, the in vitro findings are similar
to several other studies performed by our lab which showed that various dietary constituents can
increase cell metabolism and mitochondrial content in skeletal muscle cells [8, 22, 23]. These
observations also parallel those of other previous investigations that measured the effects of
dietary stimulants such as caffeine on similar metabolic parameters in L6 myotubes and C2C12
myocytes [19, 32, 33].
In agreement with previous in vitro observations using similar dietary supplements, RF increases
metabolic rate in healthy adult male subjects [16-18]. Several similarities exist between
supplements designed to stimulate metabolism including stimulants such as caffeine which have
previously been documented to increase metabolism in humans [4, 5, 7, 9, 34]. We have recently
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discussed many of these similarities including ingredient composition and effect on resting
energy expenditure [35]. Despite these findings, it is unclear to what extent energy expenditure is
increased for the purpose of weight loss. Because our measurements were limited to 3 hours,
several questions remain unanswered about the effects of RF. First, at what point following a
single dose does resting energy expenditure return to normal? Are these effects diminished with
ongoing use (i.e. sensitization)? Are these effects also seen in older adults and women? Will
increases in systolic blood pressure resolve with use? Our data adds to the current literature
which supports the hypothesis that dietary composition may play a vital role in human energy
homeostasis and energy balance. Proprietary blends consisting of multiple plant extracts
potentially offer numerous diverse phytochemicals which may be useful in altering energy
expenditure, although promotional advertising makes much of current information difficult for
consumers to trust. Currently there is an immense interest in both private and commercial sectors
for exploring extracts (such as green tea) and food-stuff for the benefit of metabolic disease
including obesity and diabetes supporting the need for ongoing research in dietary supplements
and functional food chemicals [34].

Conclusion
Dietary supplements are generally regarded as ineffective, under-researched, and potentially
risky by the medical community. Despite this general consensus, there is an increasing interest in
alternative methods to increase metabolism and fat loss. Our observations support the hypothesis
that RF may be effective at increasing metabolic rate in vitro and in vivo. Although many
supplements are commercially available for consumption and are advertised to increase
metabolism and cause weight loss, few supplements have non-biased data supporting claims of
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efficacy. There are many therapies that are currently recommended to promote weight loss.
However, dietary supplements are generally not regarded as a part of the standard of care for
weight loss. Further research is needed to elucidate the full effects of habitual RF consumption
on human metabolism and health.
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Current research has outlined many of the potential benefits that dietary ingredients may provide
for metabolic disease. Stimulation of metabolic gene expression (including PGC-1α expression)
via dietary metabolites may result in increase in oxidative capacity, which may provide some
benefit for metabolic disease including diabetes and obesity. Further investigation is required to
elucidate the full potential efficacy of dietary PGC-1 stimulators for metabolic disease. Dietary
supplements are generally regarded as ineffective, under-researched, and potentially risky by the
medical community. Despite this general consensus, there is an increasing interest in alternative
methods to increase metabolism and fat loss. Our observations, along with those generated from
several other groups support the hypothesis that dietary supplements may effectively increase
metabolic rate. Many supplements are commercially available for consumption and are
advertised to increase metabolism and cause weight loss. Few supplements have non-biased data
supporting claims of efficacy. From the available evidence, it appears that commercially
available dietary supplements advertised to stimulate metabolism have the propensity to increase
metabolic rate, at least immediately following ingestion. Despite significant increases in resting
energy expenditure, it is doubtful that commercially available thermogenic products stimulate
metabolism more than consumption of food products containing equivocal content of
caffeine/stimulants and/or polyphenols. Moreover, it should be mentioned that increases in
metabolism induced by food or dietary supplements are small, contributing only subtly to
metabolic rate. Further research is needed to elucidate the full effects of habitual dietary
supplement consumption on human metabolism and health. Specifically, further research to
elucidate the effects that dietary stimulators of metabolism have on various demographics
including female and obese subjects. This includes evidence which speaks to ongoing safety and
therapeutic doses for both men and women of various ages and body sizes. Lastly, future

81

investigation is required to identify other molecular effects that dietary supplements have, which
could lead to identification of future therapeutic targets.
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Appendix 1 Individual subject variables
Subject Variables
Subject

Weight (kg)

Height (m)

BMI

Fat%

LBM(kg)

Caffeine (mg)

Δ REE

age

1.00

89.80

1.78

28.25

13.90

77.32

32.00

281.35

28.00

2.00

68.60

1.77

21.90

10.63

61.31

375.00

251.05

22.00

3.00

71.60

1.84

21.26

5.50

67.66

180.00

113.01

31.00

4.00

69.80

1.67

25.03

8.19

64.08

412.50

141.86

30.00

5.00

81.40

1.72

27.51

20.00

65.12

450.00

6.24

26.00

6.00

75.60

1.75

24.83

6.68

70.55

450.00

123.14

26.00

7.00

71.00

1.71

24.28

16.40

59.36

100.00

49.15

26.00

8.00

86.00

1.75

28.08

24.00

65.36

300.00

203.41

24.00

9.00

72.80

1.75

23.77

21.25

57.33

225.00

244.14

33.00

10.00

90.91

1.79

28.50

21.25

71.59

400.00

183.61

21.00

Ave

77.75

1.75

25.34

14.78

65.97

292.45

159.70

26.70

SD

8.56

0.05

2.65

6.76

6.05

150.76

89.67

3.86
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Appendix 2 Change in individual subject resting energy expenditure
REE (kcal/day)
Baseline

1 hr

2 hr

Average

STDEV

Subject

Control

RF

Control

RF

Control

RF

Control

RF

Control

RF

1.00

1853.95

2165.73

1830.14

2001.86

1871.85

2232.41

1851.98

2133.33

20.92

118.64

2.00

1830.38

1861.50

1542.10

1845.61

1586.66

2005.18

1653.04

1904.10

155.18

87.90

3.00

1770.78

1793.33

1637.72

1867.95

1703.10

1789.36

1703.87

1816.88

66.53

44.27

4.00

1483.18

1602.60

1357.21

1604.52

1365.64

1424.49

1402.01

1543.87

70.42

103.39

5.00

1884.07

1924.05

1873.63

1854.27

1937.48

1935.59

1898.39

1904.64

34.25

44.00

6.00

2071.44

2191.18

1980.51

2069.46

1935.22

2095.95

1995.72

2118.86

69.37

64.02

7.00

1511.82

1600.64

1561.92

1608.00

1491.10

1503.66

1521.62

1570.77

36.41

58.23

8.00

1843.55

2122.64

2121.38

1947.07

1745.37

2250.84

1903.43

2106.85

195.03

152.50

9.00

1498.28

1714.37

1408.60

1691.70

1479.76

1713.01

1462.22

1706.36

47.34

12.71

10.00

1787.48

1879.74

1845.31

1985.00

1803.29

2122.18

1812.03

1995.64

29.89

121.57

Ave

1753.49

1885.58

1715.85

1847.54

1691.95

1907.27

1720.43

1880.13

72.54

80.72

SD

194.45

218.39

252.15

164.33

202.79

291.27

205.22

218.58

57.52

43.35
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Appendix 3 Change in individual subject respiratory exchange ratio
RER (VCO2/VO2)
Baseline

1 hr

2 hr

Average

STDEV

Subject

Control

RF

Control

RF

Control

RF

Control

RF

Control

RF

1.00

0.90

0.85

0.88

0.85

0.89

1.06

0.89

0.92

0.01

0.12

2.00

0.90

0.92

0.84

0.92

0.86

0.97

0.87

0.94

0.03

0.03

3.00

0.93

1.09

0.95

1.12

0.90

1.04

0.93

1.08

0.03

0.04

4.00

0.97

0.94

0.96

0.92

0.97

0.86

0.97

0.91

0.01

0.04

5.00

0.85

0.97

0.84

0.92

0.84

0.94

0.84

0.94

0.01

0.03

6.00

0.86

0.82

0.86

0.79

0.85

0.88

0.85

0.83

0.01

0.04

7.00

0.87

1.01

0.89

1.05

0.89

0.91

0.89

0.99

0.01

0.07

8.00

0.99

1.05

1.01

0.96

0.95

1.01

0.98

1.01

0.03

0.05

9.00

0.89

0.91

0.86

0.93

0.91

0.85

0.88

0.90

0.03

0.04

10.00

0.99

0.97

0.96

0.96

0.96

0.99

0.97

0.97

0.02

0.01

Ave

0.91

0.95

0.91

0.94

0.90

0.95

0.91

0.95

0.02

0.05

SD

0.05

0.08

0.06

0.09

0.05

0.08

0.05

0.07

0.01

0.03
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Appendix 4 Change in individual subject Systolic blood pressure
Systolic BP (mmHg)
Baseline

1 hr

2 hr

Average

STDEV

Subject

Control

RF

Control

RF

Control

RF

Control

RF

Control

RF

1.00

88.00

82.00

98.00

104.00

96.00

102.00

94.00

96.00

5.29

12.17

2.00

108.00

114.00

112.00

120.00

106.00

112.00

108.67

115.33

3.06

4.16

3.00

106.00

112.00

112.00

116.00

106.00

118.00

108.00

115.33

3.46

3.06

4.00

106.00

98.00

94.00

102.00

94.00

102.00

98.00

100.67

6.93

2.31

5.00

110.00

108.00

112.00

112.00

110.00

108.00

110.67

109.33

1.15

2.31

6.00

116.00

122.00

124.00

120.00

118.00

120.00

119.33

120.67

4.16

1.15

7.00

120.00

120.00

118.00

118.00

130.00

120.00

122.67

119.33

6.43

1.15

8.00

104.00

116.00

102.00

104.00

108.00

106.00

104.67

108.67

3.06

6.43

9.00

102.00

106.00

104.00

112.00

108.00

102.00

104.67

106.67

3.06

5.03

10.00

114.00

118.00

114.00

120.00

118.00

118.00

115.33

118.67

2.31

1.15

Ave

107.40

109.60

109.00

112.80

109.40

110.80

108.60

111.07

3.89

3.89

SD

8.85

12.07

9.30

7.19

10.63

7.73

8.94

8.29

1.82

3.41
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Appendix 5 Change in individual subject diastolic blood pressure
Diastolic BP (mmHg)
Baseline

1 hr

2 hr

Average

STDEV

Subject

Control

RF

Control

RF

Control

RF

Control

RF

Control

RF

1.00

56.00

56.00

58.00

62.00

64.00

62.00

59.33

60.00

4.16

3.46

2.00

64.00

66.00

68.00

82.00

68.00

76.00

66.67

74.67

2.31

8.08

3.00

70.00

62.00

62.00

64.00

66.00

70.00

66.00

65.33

4.00

4.16

4.00

56.00

54.00

62.00

52.00

64.00

56.00

60.67

54.00

4.16

2.00

5.00

60.00

68.00

62.00

70.00

56.00

76.00

59.33

71.33

3.06

4.16

6.00

66.00

58.00

74.00

64.00

70.00

70.00

70.00

64.00

4.00

6.00

7.00

82.00

84.00

80.00

84.00

84.00

84.00

82.00

84.00

2.00

0.00

8.00

66.00

70.00

68.00

70.00

64.00

64.00

66.00

68.00

2.00

3.46

9.00

68.00

76.00

56.00

74.00

76.00

76.00

66.67

75.33

10.07

1.15

10.00

78.00

78.00

80.00

80.00

78.00

82.00

78.67

80.00

1.15

2.00

Ave

66.60

67.20

67.00

70.20

69.00

71.60

67.53

69.67

3.69

3.45

SD

8.54

9.99

8.60

10.09

8.23

8.93

7.65

9.22

2.49

2.37
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Appendix 6 Individual subject treatment schedule (determined randomly by a third party via random.org)
Subject #

Trial 1

1

Placebo

RF

2

RF

Placebo

3

Placebo

RF

4

RF

Placebo

5

Placebo

RF

6

RF

Placebo

7

RF

Placebo

8

Placebo

RF

9

Placebo

RF

10

RF

Placebo
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Trial 2

Supplemental Figure 1. (A) Cell viability of RD cells treated with RF at either 100 µM or 200 µM for 24
hours. (B) Cell viability of C2C12 cells treated with RF at either 10 µM or 20 µM for 24 hours.
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